M Hedenus

Summary

Affiliation: Sundsvall Hospital
Country: Sweden

Publications

  1. ncbi Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy
    M Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    J Clin Pharm Ther 33:365-74. 2008
  2. ncbi Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
    Michael Hedenus
    Sundsvall Hospital, Sundsvall, Sweden
    Leuk Lymphoma 53:2151-8. 2012
  3. ncbi Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
  4. ncbi The role of iron supplementation during epoietin treatment for cancer-related anemia
    M Hedenus
    Department of Medicine, Sundsvall Hospital, 851 86 Sundsvall, Sweden
    Med Oncol 26:105-15. 2009
  5. ncbi Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
    M Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    Leukemia 21:627-32. 2007
  6. ncbi Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall S 851 86, Sweden
    J Clin Oncol 23:6941-8. 2005
  7. ncbi Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 122:394-403. 2003
  8. ncbi Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies
    Timothy J Littlewood
    John Radcliffe Hospital, Oxford, United Kingdom
    J Pain Symptom Manage 31:317-25. 2006
  9. ncbi A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia
    Dusan Kotasek
    Ashford Cancer Centre, Ashford, Australia
    Curr Med Res Opin 23:1387-401. 2007
  10. ncbi Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 129:206-9. 2005

Detail Information

Publications11

  1. ncbi Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy
    M Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    J Clin Pharm Ther 33:365-74. 2008
    ..05). The present analysis aimed to investigate whether a combination of epoetin beta and IV iron is cost-effective compared with epoetin beta without IV iron...
  2. ncbi Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
    Michael Hedenus
    Sundsvall Hospital, Sundsvall, Sweden
    Leuk Lymphoma 53:2151-8. 2012
    ..In this meta-analysis, ESAs reduced transfusions with no clear effect on mortality or disease progression in patients with lymphoproliferative malignancies receiving chemotherapy...
  3. ncbi Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
    ..In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level < or = 10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care...
  4. ncbi The role of iron supplementation during epoietin treatment for cancer-related anemia
    M Hedenus
    Department of Medicine, Sundsvall Hospital, 851 86 Sundsvall, Sweden
    Med Oncol 26:105-15. 2009
    ..Recommendations concerning the optimal formulation, doses, and schedule of iron supplementation to ESA treatment in cancer-related anemia are provisional awaiting data from prospective, randomized trials...
  5. ncbi Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study
    M Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    Leukemia 21:627-32. 2007
    ..051). In conclusion, the Hb increase and response rate were significantly greater with the addition of intravenous iron to epoetin treatment in iron-replete patients and a lower dose of epoetin was required...
  6. ncbi Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall S 851 86, Sweden
    J Clin Oncol 23:6941-8. 2005
    ..To determine the effect of darbepoetin alfa (DA) on progression-free survival (PFS) and overall survival (OS) in patients with chemotherapy-induced anemia (CIA)...
  7. ncbi Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 122:394-403. 2003
    ..Darbepoetin alfa significantly increased haemoglobin and reduced red blood cell transfusions in patients with lymphoproliferative malignancies receiving chemotherapy...
  8. ncbi Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies
    Timothy J Littlewood
    John Radcliffe Hospital, Oxford, United Kingdom
    J Pain Symptom Manage 31:317-25. 2006
    ..001) greater improvements in all other scales, except the FACT Social subscale. Managing anemia-related fatigue appears to have a positive impact on HRQOL, enhancing cancer patients' activity levels, mood, and perceived overall health...
  9. ncbi A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia
    Dusan Kotasek
    Ashford Cancer Centre, Ashford, Australia
    Curr Med Res Opin 23:1387-401. 2007
    ..To evaluate if a darbepoetin alfa correction/maintenance dosing regimen is non-inferior to a weekly regimen with respect to red blood cell transfusion requirements in patients with chemotherapy-induced anemia (CIA)...
  10. ncbi Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study
    Anders Osterborg
    Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 129:206-9. 2005
    ..76). This long-term follow up indicated that epoetin-beta has no significant effect on survival compared to placebo in anaemic patients with lymphoproliferative malignancies...
  11. ncbi Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
    Michael Hedenus
    Medical Department, Sundsvall Hospital, Sundsvall, Sweden
    Br J Haematol 119:79-86. 2002
    ..Confirmative studies at doses of 2.25 and/or 4.5 microg/kg/week in this population are warranted...